Presentation is loading. Please wait.

Presentation is loading. Please wait.

Pulmonary Function Testing in Cystic Fibrosis

Similar presentations


Presentation on theme: "Pulmonary Function Testing in Cystic Fibrosis"— Presentation transcript:

1 Pulmonary Function Testing in Cystic Fibrosis
Ramachandra R. Sista, MD Division of Pulmonary & Critical Care Medicine Stanford University

2 Cystic Fibrosis – Multisystem disorder
CFTR [Ion Channel] ‘Mutations’ Defective epithelial salt and fluid transport 1 in 2-3K live births in US

3 Cystic Fibrosis - Airways
Respiratory Tract/Sinus disease Chronic airway Inflammation Colonization by bacteria Rhinosinusitis Nasal polyps Bronchitis/bronchiectasis Hemoptysis Productive cough Copious sputum production/secretions Lung hyperinflation PFT evidence for obstructive ventilatory limitation

4 CF – Airways

5 Cystic Fibrosis – Lung Function

6 Respiratory Pump Thorax Diaphragm Abdomen Abdomen

7 Airways [Trachobronchial tree]

8 Gas Exchange [Functional units]

9 Pulmonary Function Testing [PFT]
Spirometry (Flow Volume Loop) ± BDR Lung volumes Diffusion capacity (DLCO)

10 Spirometry Simple, reproducible and office-based
How much of air can you move? - in & out - [vital capacity] How fast can you move? - in & out - [flow / time] Based on these two - FVC and FEV1

11 Spirometry Monitoring of spirometry – simple and quick
Early recognition and quick intervention for pulmonary decline / acute exacerbation Minimize loss of lung function

12 Impact of Respiratory Pathogens
Staph (MRSA, MSSA) Pseudomonas (mucoid, non-mucoid, MDR) Haemophilus influenza Stenotrophamonas maltophilia Burkholderia cepacia Achromobacter xylocans Non-tuberculous mycobacteria [NTM – eg. MAC] Aspergillus species [ABPA]

13 Impact of Respiratory Pathogens

14 Impact of Airway therapies
Pulmonary therapies Antibiotics (PO, IV, IH) Macrolide therapy (anti-inflammatory/neutrophil) Bronchodilators Treatment of ABPA DNAase (Dornase, Pulmozyme) Hypertonic saline N-acetylcysteine Chest physiotherapy Exercise

15 Hypertonic saline

16 Anti Inflammatory Agents

17 CFRD, Nutrition and Lung function
Very important part of successful CF management Aggressive management of CFRD Neutrophil dysfunction Associated with accelerated loss of lung function Increased mortality risk

18 Nutrition and BMI FEV1 percent is positively correlated with BMI percentile for patients 20 to 40 years of age (correlation = 0.92, p < )

19 CFRD – Glucose Control – FEV1
Semin Respir Crit Care Med 2007

20 Cystic Fibrosis - Cornerstones
Airway clearance Dornase alfa (2.5 mg nebulized daily) Nebulized antibiotics Oral azithromycin Inhaled hypertonic saline [7% 2-4 times per day] Aggressive antibiotic therapy for exacerbations Nutritional support (high-caloric, high-salt diet) Replacement of fat-soluble vitamins [A, D, E, K] Exercise

21 Cystic Fibrosis - Cornerstones
Airway clearance Dornase alfa (2.5 mg nebulized daily) Nebulized antibiotics Oral azithromycin Inhaled hypertonic saline [7% 2-4 times per day] Aggressive antibiotic therapy for exacerbations Nutritional support (high-caloric, high-salt diet) Replacement of fat-soluble vitamins [A, D, E, K] Exercise

22 Acknowledgement David Weill, MD Pediatric Pulmonologists Gundeep Dhillon, MD Paul Mohabir, MD Kathy Gesley Nicole Eden Lara Freet Lesley Seeger CF Clinical Research Team


Download ppt "Pulmonary Function Testing in Cystic Fibrosis"

Similar presentations


Ads by Google